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OBJECTIVES The purpose of this study was to examine the variability in cytokines and cytokine receptors
in patients with heart failure in comparison with a group of healthy control subjects who were
free of cardiovascular disease.
BACKGROUND Despite increasing interest in cytokines as mediators of disease progression in heart failure
and the recent interest in suppressing cytokines in clinical studies, the extent of variability in
cytokines and cytokine receptors is largely unknown. This information is important for
interpreting the results of studies in which changes in cytokine levels are measured in response
to a specific form of therapy.
METHODS Circulating levels of tumor necrosis factor-alpha (TNF-a), and soluble TNF receptors (types
1 and 2), as well as interleukin (IL)-6 and IL-6 receptor were measured on a daily, weekly and
monthly basis in heart failure patients (New York Heart Association class IIIa and IIIb; n 5
10) and healthy volunteer subjects (n 5 10). Measurements of cytokines and cytokine
receptors were performed on plasma samples by enzyme-linked immunoassay. The daily,
weekly and monthly degree of variability in cytokine and cytokine receptor levels was assessed
by determining the coefficient of variation each point in time.
RESULTS The coefficient of variation for TNF-a and IL-6 levels increased over time in patients with
heart failure; moreover, the coefficient of variation in heart failure subjects was significantly
greater for IL-6 than for TNF-a. The coefficient of variation in cytokine receptor levels was
minimal, and did not differ significantly between heart failure and control subjects.
CONCLUSIONS In patients with heart failure the degree of natural variability in circulating cytokine levels
increases with time, and is greater for IL-6 than for TNF-a. Accordingly, the results of the
present study suggest that the sample size needed to show a statistically significant change in
the circulating level of a given cytokine will vary depending on the specific cytokine that is
being measured, as well as the time period over which that cytokine is being assayed. (J Am
Coll Cardiol 1999;33:1935–42) © 1999 by the American College of Cardiology
Despite repeated attempts to develop a unifying hypothesis
that explains the clinical syndrome of heart failure, no single
conceptual paradigm has withstood the test of time. That is,
whereas clinicians have tended to view heart failure as an
edematous state, or alternatively a hemodynamic disorder,
more recent studies have suggested that the excessive
elaboration of biologically active molecules may play an
important role in the pathogenesis of heart failure by virtue
of the direct toxic effects that these molecules exert on the
heart and the circulation (1). In this regard, one of the more
recent interesting and intriguing observations in clinical
heart failure research is that in addition to the classic
neurohormones that are elaborated in heart failure, a second
portfolio of biologically active molecules, termed proinflam-
matory cytokines, are also overexpressed in heart failure (2).
Given that cytokines have been shown to produce pulmo-
nary edema and left ventricular dysfunction in human
subjects (3–5), there has been increasing interest in studying
the role that these molecules may play as biologic mediators
of disease progression in heart failure. Accordingly, it is
perhaps not surprising that a number of experimental and
clinical studies have begun to examine the levels of cytokines
and cytokine receptors in response to various forms of
treatment (6–11).
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To assess the influence of a given therapeutic intervention
from either a clinical or biologic point of view, it is essential
to understand the natural degree of variability in the end
points that are being targeted for therapeutic intervention.
Thus far, however, the extant information with respect to
the natural variability in cytokines and cytokine receptors in
patients with heart failure has been extremely limited
(12,13). Moreover, there is no information with regard to
whether or not the degree of cytokine variability in subjects
with heart failure is more or less than the degree of
variability that is observed in healthy subjects. Therefore,
the purpose of this study was to prospectively assess the
degree of daily, weekly and monthly variability in cytokines
and cytokine receptors in patients with moderate to ad-
vanced heart failure in comparison with a group of healthy
volunteers who were studied over a similar time period.
METHODS
Subject demographics. To examine the natural variability
of cytokines and cytokine receptors in patients with heart
failure, we selected 10 consecutive volunteers from the heart
failure clinic at the Houston Veterans Affairs Medical
Center. All of the patients had New York Heart Association
(NYHA) classification class III heart failure, and were on
stable medical therapy for at least one month before
enrollment in the study. The patients had to give informed
consent and be available for the daily, weekly and monthly
follow-up visits during the four-month duration of the
study. The cohort of control subjects for this study com-
prised healthy volunteers selected randomly from the Hous-
ton Veterans Affairs Medical Center population. All of
these subjects were screened for the absence of organic heart
disease by history, physical examination, 12-lead electrocar-
diography and two-dimensional echocardiography. Heart
failure and normal volunteers were excluded from the study
if they had a viral or bacterial infection within a two-week
period of the study. The research protocol was approved by
the Institutional Board for Human Subject Research for
Baylor College of Medicine.
After the initial baseline visit (day 1), each of the control
and heart failure subjects had a total of seven follow-up
visits, including visits on days 2, 3, 8 (week 2), 15 (week 3),
22 (week 4), 50 (week 8) and 78 (week 12). This permitted
the assessment of variability in cytokine and cytokine
receptor levels on a daily (days 1 to 3), weekly (weeks 1 to
4) and monthly (months 1 to 4) basis.
Circulating levels of cytokines and cytokine receptors.
The methods for measuring cytokines and cytokine recep-
tors have been reported previously in detail, and were
adhered to throughout this protocol (14,15). All cytokine
and cytokine receptor assays were performed using commer-
cially available enzyme-linked immunosorbent assay kits
(Quantikine HS, R & D Systems, Minneapolis, Minnesota)
as described previously (14,15). All assays for cytokines and
cytokine soluble receptors were measured in duplicate. In
addition, we performed serial dilutions to be certain that the
level of cytokine immunoreactivity declined in a manner
parallel to the standard curve (16). All samples for a given
patient were analyzed on the same enzyme-linked immu-
nosorbent assay plate to minimize intraassay variability. The
intraassay coefficients of variation for tumor necrosis factor-
alpha (TNF-a), interleukin-6 (IL-6), soluble type 1 TNF re-
ceptor (sTNFR1), soluble type 2 TNF receptor (sTNFR2) and
soluble IL-6 receptor (sIL-6R) are 6.1%, 3.7%, 5.0%, 2.8% and
4.5%, respectively. The respective interassay coefficients of
variation for TNF-a, IL-6, sTNFR1, sTNFR2 and sIL-6R
are 7.8%, 3.6%, 5.2%, 3.6% and 5.1%. The lower limit of
sensitivity of these kits for detecting cytokines and cytokine
receptors is (pg/ml): TNF-a (0.18), IL-6 (0.09), sTNFR1
(3.5), sTNFR2 (1.0) and sIL-6R (0.5) (14).
For these studies we assessed the variability in circulating
levels of TNF-a and IL-6, based on the repeated observa-
tion that these cytokines are consistently elevated in heart
failure (2,17). We elected not to measure circulating levels
of IL-1-beta, based on the observation from this laboratory
(unpublished observation) and other laboratories (18–20)
that circulating levels of IL-1-beta are not elevated in
patients with heart failure. In addition to measuring cyto-
kines, we also elected to measure circulating levels of the
soluble cytokine receptors, because these receptors have
been shown to regulate the bioactivity of TNF-a and IL-6.
For example, sTNFR1 and sTNFR2 have been shown to
neutralize the effects of TNF-a (21), whereas sIL-6R has
been shown to increase the bioactivity of circulating IL-6
(22).
Variability in circulating levels of cytokines and cytokine
receptors. To assess the variability of cytokines, we deter-
mined the coefficient of variation for the levels of cytokines
and cytokine receptors for heart failure and control subjects
(23). The coefficient of variation was defined as the standard
deviation of the cytokine or cytokine receptor levels divided
by the mean level of the respective cytokine or cytokine
receptor level (24). Accordingly, the daily coefficient of
variation for individual patients was obtained by determin-
ing the mean and standard deviation for the cytokine or
cytokine receptor levels on days 1, 2 and 3 of the study.
Similarly, the weekly and monthly coefficient of variation
for individual patients was obtained, respectively, by deter-
mining the mean and standard deviation for the cytokine or
Abbreviations and Acronyms
ANOVA 5 analysis of variance
IL-6 5 interleukin-6
NYHA 5 New York Heart Association
sIL-6R 5 soluble interleukin-6 receptor
sTNFR1 5 soluble type 1 TNF receptor
sTNFR2 5 soluble type 1 TNF receptor
TNF-a 5 tumor necrosis factor-alpha
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cytokine receptor levels on week 1 (day 1), 2, 3, 4 (weekly
variability) and on week 1 (day 1), week 4, week 8 and week
12 (monthly variability) of the study. The average daily,
weekly and monthly coefficient of variation for all patients
was determined from the mean of the daily, weekly and
monthly coefficients of variation for individual patients.
Statistical analysis. Neither the cytokine nor the cytokine
receptor data were normally distributed; therefore, these
data were subjected to logarithmic transformation (14,25).
However, to permit comparison with results from other
studies, both the cytokine and cytokine receptor data are
presented as mean 6 SEM. A nonpaired t test was used to
compare all continuous variables (age, heart rate, blood
pressure and ejection fraction) in the heart failure and
control subjects, whereas a Fisher exact test or chi-square
test was used for the nominal variables (gender, race). The
log-normalized coefficient of variation for the daily, weekly
and monthly variability in cytokine and cytokine receptor
levels between control and heart failure subjects was com-
pared using a nonpaired t test. To confirm that this analysis
was robust, we repeated the analysis using the Wilcoxon
rank-sum test on non–log-transformed data. Two-way re-
peated measures analysis of variance (ANOVA) was used to
test for mean differences between and within heart failure
and control subjects in circulating cytokines and cytokine
receptors as a function of time. The Pearson product–
moment correlation analysis of the log-normalized data was
used to test for significant relationships between cytokines
and individual patient age. To confirm that this parametric
analysis was robust, we repeated the above analysis using the
Spearman rank-order test on non–log-transformed data.
Data (Cary, North Carolina) were analyzed using Sigma
Stat (Chicago, Illinois), Primer (McGraw Hill, New York,
New York) and SAS statistical packages. A significant
difference was said to exist at p , 0.05.
RESULTS
Subject demographics. Table 1 summarizes the demo-
graphics for the subjects with heart failure (n 5 10) and the
normal volunteers (n 5 10). As shown, the mean age for the
heart failure group was significantly higher than that for the
control group (p , 0.001). The subjects in the heart failure
and control groups were primarily male, reflecting the
demographics of the Houston Veterans Administration
Hospital; there was, however, no significant difference in
the frequency of male and female subjects between the two
groups. The racial composition of the two groups was not
significantly different (p 5 0.48), and consisted of eight
white subjects and two African-American subjects in the
heart failure cohort, and six white subjects, three African
American subjects and one Asian-American subject in the
control group. All the heart failure patients had stable
NYHA class IIIa or IIIb heart failure and were not
edematous at the time they were enrolled in the study. The
patients’ functional class remained stable throughout the
study. The etiology of heart failure was ischemic in origin in
60% of the patients; the remaining 40% of the patients were
considered to have idiopathic dilated cardiomyopathy. The
heart failure patients were on standard triple therapy for
heart failure, including angiotensin-converting enzyme in-
hibitors (100%), digoxin (80%) and diuretics (90%). There
were no changes in the dosages of these drugs during the
three-month period of observation. At the time that these
studies were conducted, the use of beta-adrenergic blocking
agents for heart failure was not routinely recommended;
therefore, only one of the heart failure patients was using a
beta-blocker. None of the heart failure patients nor the
control subjects was taking medications that were known to
alter TNF-a or IL-6 levels. As shown in Table 1, there was
no significant difference in the baseline heart rate, systolic
blood pressure and diastolic blood pressure between the
heart failure and control subjects. However, the mean
ejection fraction was significantly lower in the heart failure
patients when compared with control subjects (p , 0.001).
Circulating levels of cytokines and cytokine receptors.
To determine whether the circulating levels of cytokines and
cytokine receptors remained stable in the heart failure and
control subjects during the course of the study, we compared
the mean levels of cytokines and cytokine receptors at
baseline, and then at monthly intervals for a period of four
months. Figure 1A to C shows two important findings with
respect to the levels of TNF-a and soluble TNF receptors.
First, the mean values for TNF-a and soluble TNF recep-
tors sTNFR1 and sTNFR2 were higher in the heart failure
group compared with the control group throughout the
study. Second, the mean levels for TNF-a, sTNFR1 and
sTNFR2 remained stable as a function of time within both
the heart failure and control subjects. Two-way repeated
measures ANOVA showed that there was an overall signif-
icant difference in TNF-a, sTNFR1 and sTNFR2 levels
Table 1. Demographics and Clinical Characteristics at Baseline
Baseline Characteristics Control HF
Age (yr) 33.1 6 2.4 59.1 6 2.2*
Gender (male/female) 9/1 10/0
NYHA classification N/A III
Hemodynamics
Heart rate (beats/min) 70.7 6 5.8 68.5 6 4.0
Systolic BP (mm Hg) 119.0 6 4.7 126.9 6 7.3
Diastolic BP (mm Hg) 68.3 6 5.4 75.6 6 3.5
Ejection fraction (%) 57.5 6 2.2 27.4 6 2.2*
Medications (mg/24 h)
Lisinopril N/A 20.0 6 5.0
Furosemide N/A 84.0 6 27.6
Digoxin N/A 0.15 6 0.03
*p , 0.001 compared with values in normal subjects. All data are reported as mean 6
SEM.
BP 5 blood pressure; HF 5 heart failure; N/A 5 not applicable; NYHA 5 New
York Heart Association.
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between the control and heart failure groups (p , 0.001);
however, there was no significant difference (p . 0.05) in
the mean levels of TNF-a, sTNFR1 or sTNFR2 within the
heart failure and control groups as a function of time.
Figure 2A and B depicts the mean values for IL-6 and
sIL-6R in the heart failure and control subjects. As shown,
the mean values for IL-6 were higher in the heart failure
group compared with the control group throughout the
course of the study. In contrast, the mean levels of sIL-6R
were similar in both the heart failure and the control
subjects. The mean levels for IL-6 and sIL-6R remained
stable in both the heart failure and control subjects. Two-
way repeated measures ANOVA showed that there was an
overall significant difference in the mean IL-6 levels be-
tween heart failure and control subjects (p 5 0.005),
whereas there was no significant difference (p 5 0.51) in the
mean levels of IL-6 within the heart failure and control
groups as a function of time. In contrast, there were no
significant within (p 5 0.96) or between (p 5 0.53) group
differences in the sIL-6R levels.
Variability in circulating levels of cytokines and cytokine
receptors. To examine the daily, weekly and monthly
variability in circulating levels of cytokines and cytokine
receptors in the heart failure and the control subjects, we
examined the coefficient of variation for the cytokines and
cytokine receptors. Figure 3 shows two salient findings with
respect to the variability in circulating TNF-a levels in heart
failure and control subjects. First, the daily (p , 0.05) and
weekly (p , 0.02) variability in TNF-a levels was signifi-
cantly greater in the control subjects than in the subjects
with heart failure. Second, there was no significant differ-
ence (p 5 0.82) in monthly variability between heart failure
and control subjects.
Figure 4 shows the daily, weekly and monthly variability
in IL-6 levels in heart failure and normal control subjects. In
contrast to the findings with TNF-a, there was a consid-
erable amount of natural variability in IL-6 levels in patients
with heart failure and in healthy control subjects. Although
there was no significant difference in either the daily (p 5
0.47) or weekly (p 5 0.51) variability between the heart
failure and normal subjects, there was a greater monthly
(p 5 0.03) variability in IL-6 levels in the heart failure
subjects when compared with the normal volunteers. Fi-
nally, to determine whether the coefficient of variation for
circulating levels of IL-6 in heart failure subjects was greater
than the coefficient of variation for circulating levels of
TNF-a in heart failure subjects, we compared the daily,
weekly and monthly coefficient of variation for these two
cytokines using a nonpaired t test. This analysis showed that
the weekly (p 5 0.01) and monthly (p , 0.001) coefficient
Figure 1. Circulating levels of tumor necrosis factor-alpha
(TNF-a) (A) and soluble TNF receptor type 1 (sTNFR1) (B) and
type 2 (sTNFR2) (C) in heart failure (HF) and control subjects.
To determine whether circulating levels of cytokine and cytokine
receptors increased over time, the mean levels of TNF-a, sTNFR1
and sTNFR2 were determined on a monthly basis for a period of
4 months (see Methods for details). Heart failure patients are
depicted by solid squares, and healthy control subjects are de-
picted by open squares.
Figure 2. Circulating levels of interleukin-6 (IL-6) (A) and soluble
IL-6 receptor (sIL-6R) (B) in heart failure (HF) and control
subjects. To determine whether circulating levels of cytokine and
cytokine receptors increased over time, the mean levels of IL-6 and
sIL-6R were determined on a monthly basis for a period of 4
months (see Methods for details). Heart failure patients are
depicted by solid squares, and healthy control subjects are de-
picted by open squares.
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of variation was significantly greater for IL-6 when com-
pared with TNF-a, whereas there was no significant dif-
ference (p 5 0.27) in the daily coefficient of variation for
IL-6 and TNF-a levels. Similar findings were obtained
when we employed the Wilcoxon rank-sum test on non–
log-transformed data.
Table 2 depicts the daily, weekly and monthly coefficient
of variation for circulating levels of cytokine receptors for
the subjects with heart failure and the healthy control
subjects. As shown, the overall variability in circulating
levels of sTNFR1, sTNFR2 and sIL-6R was relatively low
for both groups of patients, when examined on a daily,
weekly or monthly basis. Moreover, there was no statisti-
cally significant difference in the coefficient of variation, at
any point in time, between either the patients with heart
failure or the healthy control subjects.
Because the patients with heart failure were older than
the normal volunteers, we sought to determine whether
there was a significant correlation (Pearson product–
moment correlation) between the coefficient of variation for
TNF-a and IL-6 levels and the corresponding age of the
patient. This analysis showed that there was no significant
correlation between age and cytokine variability (data not
shown) when the data were examined on a daily, weekly or
monthly basis (range: r 5 20.46 to 0.37; p 5 0.18 to 0.99).
Similar results were obtained when the nonnormalized data
were analyzed with the Spearman rank-order test, suggest-
ing that the parametric analysis was robust. Nonetheless, the
effect of age on cytokine variability cannot be completely
excluded by this analysis.
DISCUSSION
Despite the increasing interest in the role that cytokines play
as potential mediators of disease progression in heart failure,
and the increasing interest in modulating cytokine levels in
clinical heart failure studies (6–11,26), virtually nothing is
known with respect to the natural variability in circulating
levels of cytokines and cytokine receptors in patients with
heart failure. To address this deficiency we prospectively
examined the variability in circulating levels of cytokine and
cytokine receptors in subjects with moderate to advanced
heart failure (NYHA class IIIa and IIIb). Analysis of the
aggregate data permits at least two important conclusions to
be drawn. First, the degree of cytokine variability appears to
depend not only on the cytokine that is being measured, but
also on the time course over which that cytokine is being
assessed. For example, we observed that the daily and
weekly variability in circulating TNF-a levels was signifi-
cantly lower in heart failure patients than in healthy subjects
(Fig. 3). However, TNF-a variability increased approxi-
mately twofold with time in the heart failure subjects, with
the result that the monthly variability in TNF-a levels was
not significantly different between heart failure and control
subjects (Fig. 3). In contrast to the findings with TNF-a,
there was a great deal of variability in IL-6 levels in both
heart failure and normal subjects (Fig. 4), regardless of
whether the variability was assessed on a daily, weekly or
monthly basis. Although there was no difference in the daily
and weekly variability in IL-6 levels between subjects with
heart failure and normal volunteers, we observed that there
was a small but statistically significant increase in monthly
variability in IL-6 levels in patients with heart failure when
Figure 3. Variability in circulating tumor necrosis factor-alpha
(TNF-a) levels in heart failure and control subjects. The degree of
TNF-a variability was assessed by determining the coefficient of
variation (CV) (see Methods) for daily, weekly and monthly
TNF-a levels. Each data point shown reflects the CV for a given
subject. Heart failure patients are depicted by closed diamonds,
and healthy control subjects are depicted by open squares. The
mean 6 SEM of the CVs in each group are shown to the right of
each scatter plot.
* 5 p , 0.05 compared with control subjects.
Figure 4. Variability in circulating interleukin-6 (IL-6) levels in
heart failure and control subjects. The degree of IL-6 variability
was assessed by determining the coefficient of variation (CV) (see
Methods) for daily, weekly and monthly IL-6 levels. Each data
point shown reflects the CV for a given subject. Heart failure
patients are depicted by closed diamonds, and healthy control
subjects are depicted by open squares. The mean 6 SEM of the
CVs in each group are shown to the right of each scatter plot.
* 5 p , 0.05 compared with control subjects.
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compared with normal volunteers (Fig. 4). Moreover, there
was an approximately fourfold increase in IL-6 variability in
the heart failure patients with time. Finally, when we
compared the average coefficient of variation for cytokine
levels in heart failure patients, we observed that the extent of
weekly and monthly variability was significantly greater for
IL-6 when compared with TNF-a. The observed differ-
ences in variability in circulating cytokine levels in the heart
failure and control subjects did not appear to be related to
increasing cytokine levels over the three-month period of
the study (Fig. 1 and 2), nor to age-related differences
between the heart failure and control subjects, insofar as we
did not observe a significant relationship between age and
cytokine variability for either group of subjects, consistent
with previous studies in healthy subjects that have not
observed a correlation between age and TNF-a and IL-6
variability (27,28). Furthermore, the natural variability in
cytokine levels in the present study was unlikely to be due to
intra- or interassay variability alone, since the observed
variability in cytokines was well in excess of the analytical
variability of the assay methodology used in the present
study (14). The second conclusion to be drawn from these
studies is that the natural variability in circulating levels of
cytokine receptors in heart failure and normal subjects is less
than that observed for the respective cognate cytokines
(Table 2). Moreover, the variability in cytokine receptors
was not significantly different in heart failure patients
compared with the normal subjects (Table 2).
Cytokine variability in heart failure. Although the precise
reason(s) for the differences in the variability in circulating
TNF-a and IL-6 levels in heart failure subjects is not
known, there are several potential explanations that warrant
discussion. One possible explanation for the differing de-
grees of variability between these two cytokines may relate
to the differing degree of stabilization of these proteins in
the peripheral circulation. That is, although TNF-a and
IL-6 are known to bind to, and to be stabilized by their
circulating cognate receptors (29–31), the degree of stabi-
lization may be quantitatively different for each cytokine.
For example, we observed that the ratio ([mol/liter]/[mol/
liter]) of (sTNFR1 1 sTNFR2)/TNF-a ranged '2,100 to
2,700 for the healthy volunteers and heart failure subjects in
this study, whereas the ratio of sIL-6R/IL-6 ([mol/liter]/
[mol/liter]) ranged '3 to 6. Thus, the increased variability
that we and others have observed for IL-6 may relate, at
least in part, to the possibility that IL-6 is degraded more
rapidly in the periphery than TNF-a is. Further support for
the point of view that increased stability may account for the
differing degrees of variability in TNF-a and IL-6 levels is
suggested by the observation that the absolute levels of
circulating TNF receptors increase in direct response to
increased TNF-a levels (“receptor shedding”) (32), whereas
the response of IL-6 receptors to increasing levels of IL-6 is
quite variable, and may increase, decrease or remain the
same (33–35). Indeed, in the present study we noted that
there was an approximately twofold increase in sTNFR1
and sTNFR2 in heart failure patients, where the levels of
sIL-6R were not significantly different in the healthy
subjects and the patients with heart failure (Fig. 2) (36,37).
The previous statements notwithstanding, it should be
recognized that a number of proteins other than sIL-6R
may serve as chaperones for IL-6, and that the transport and
stabilization of this molecule is likely to be very complex
(31). A second, intriguing explanation for the decreased
variability in TNF-a levels in the heart failure subjects may
relate to the general loss of biologic variability that has been
observed repeatedly in heart failure patients. That is, previ-
ous studies have reported a loss in heart rate variability (38),
and loss in neurohormonal variability in patients with heart
failure (39,40). Indeed, it has been suggested that loss of
“variability reserve” (41) is a sign of a biologic system that is
persistently activated, and may therefore respond less well to
superimposed physiologic/pathologic stimuli (42). How-
ever, although this concept may explain the loss of variabil-
ity in TNF-a, it does not explain the higher degree of
variability in IL-6 levels that we observed in the heart failure
patients. A third explanation for the difference in variability
between TNF-a and IL-6 in our study might simply relate
to the inherent differences in their circadian or seasonal
variation in IL-6 levels.
Although a full discussion of the natural variability in
cytokines and cytokine receptors in health and disease is
beyond the intended scope of this discussion, it bears
emphasis that the results of the present study are qualita-
Table 2. Natural Variability in Cytokine Receptors
Coefficient of
Variation (%)
sTNFR1 sTNFR2 sIL-6R
Control HF Control HF Control HF
Daily 5.7 6 1.0 4.1 6 1.3 4.9 6 0.8 4.4 6 1.3 5.6 6 1.6 3.7 6 0.7
(2.9–12.5) (0.6–14.7) (1.4–8.6) (0.5–15.1) (1.4–18.2) (1.3–7.6)
Weekly 8.3 6 1.3 5.5 6 1.1 8.2 6 1.1 6.3 6 0.9 7.5 6 2.5 7.0 6 1.1
(1.4–14.6) (1.6–12.7) (4.2–14.3) (2.3–10.5) (1.5–27.1) (2.7–13.7)
Monthly 7.8 6 1.2 7.4 6 2.0 10.8 6 2.7 9.6 6 0.9 10.1 6 2.6 9.3 6 0.8
(3.2–16.0) (2.3–24.5) (5.8–34.7) (3.9–13.3) (3.6–29.9) (4.6–13.0)
Data are presented as mean 6 SEM and as the range for the coefficient of variation (shown below in parentheses).
HF 5 heart failure; sIL-6R 5 soluble interleukin-6 receptor; sTNFR1, sTNFR2 5 soluble TNF receptor types 1 and 2.
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tively similar to those reported by Masson et al. (13), who
studied the natural variability in IL-6 and sTNFR1 levels in
18 heart failure subjects (NYHA class II/III) over a three-
week period. The calculated coefficient of variation for IL-6
and sTNFR1 in their study was '195% and '7%, respec-
tively, which was somewhat higher than we observed in the
present study. Although the reasons for the greater degree
of variability in IL-6 levels in the study by Masson et al. (13)
are not known, they may relate to the fact that these
investigators determined cytokine variability based on two
measurements three weeks apart, whereas we assessed IL-6
variability based on cytokine determinations at four separate
time points, each one week apart. The results of the present
study differ somewhat from those reported by Dutka et al.
(12), who measured TNF-a levels serially every three
months for one year in patients with NYHA class IV heart
failure. These investigators did not directly determine a
coefficient of variation for TNF-a levels in their study, but
did report that TNF-a levels were below the limit of
detection of their assay on at least one occasion in all 16 of
their patients, thus leading them to conclude that there was
“considerable between and within patient variation” in
TNF-a levels in their study. The most likely explanation for
the difference between their report and the present study is
that the TNF-a assay they used was '150-fold less sensi-
tive than the one used in the present study. Thus, it is
possible that the inability to detect a circulating TNF-a
level in their study was the result of the assay that was
employed, as opposed to a high degree of variability in
TNF-a levels in their patients with heart failure. However,
we cannot exclude the possibility that the NYHA class IV
patients in their study may have had a greater degree of
variability in TNF-a levels than the NYHA class III
patients we examined in the present study.
There are several limitations of the present study that
bear emphasis. First, the overall sample size of the present
study was relatively small, which was due in large part to the
difficulty in finding stable heart failure patients who were
willing to return to the hospital for the frequent visits.
Nonetheless, this relatively small sample size did not pre-
clude obtaining statistically significant results with respect
to the variability in TNF-a and IL-6 levels. Second, all
patients had moderate heart failure (NYHA class IIIa and
IIIb); accordingly it is unclear if our results will be relevant
for patients with milder or more advanced degrees of heart
failure. Nonetheless, the levels of cytokines in our study
overlap with those reported for patients with NYHA IV
heart failure (15). Thus, it is possible that our findings may
also apply to patients with more advanced heart failure.
Conclusions. In assessing the impact of a given therapeutic
intervention from either a biologic or a statistical point of
view, it is necessary to first understand the natural degree of
variability in the end points that one has chosen to target.
Given the recent interest in cytokines as therapeutic targets
in the setting of heart failure, the results of the present study
would appear to be important for at least two reasons. First,
the results of the present study suggest that the sample size
needed to show a statistically significant change in the
circulating level of a given cytokine after a therapeutic
intervention will vary, depending on the specific cytokine
that is being measured, as well as the time period over which
that cytokine is being assayed (Fig. 3 and 4, Table 3). As
one theoretical example, the data in the present study
suggest that for a given therapeutic intervention to detect a
15% change in either circulating TNF-a or IL-6 levels over
a four-month period (alpha 5 0.05; power 5 0.80), it would
require a sample size of 21 and 377 patients, respectively
(Table 3) to show a statistically significant difference. Thus,
the sample size needed to show a statistically significant
difference may vary at least 18-fold, depending on the
particular cytokine that one intends to target. A second
important, and potentially disconcerting implication of this
study is that it may not be possible to relate specific changes
in circulating levels of certain cytokines with specific
changes in outcome measures in individual heart failure
patients with any degree of confidence, because of the
tremendous amount of intrasubject variability in cytokine
levels. The above statements are in no way intended to offer
a disparaging or discouraging commentary on the impor-
tance of assessing changes in circulating cytokines in the
setting of heart failure; however, they do suggest that studies
that are designed to assess changes in circulating cytokine
levels in patients with heart failure should not be undertaken
casually, and that all such studies should be appropriately
designed to avoid drawing conclusions that may lack bio-
logic or clinical significance.
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